Affiliation:
1. Susan Lehman Cullman Laboratory for Cancer Research Rutgers University Piscataway New Jersey USA
2. Graduate Program in Cellular and Molecular Pharmacology Rutgers University Piscataway New Jersey USA
3. Rutgers Cancer Institute of New Jersey New Brunswick New Jersey USA
Abstract
AbstractMelanoma is the most aggressive type of skin cancer and is responsible for the majority of deaths from skin cancer. Therapeutic advances in the last few decades, notably the development of novel targeted therapies and immunotherapies have significantly improved patient outcomes; nonetheless, these options remain limited due to the onset of resistance to treatment modalities and relapse. In this review, we focus on the available therapeutic options, their benefits, and limitations.
Funder
National Cancer Institute
Rutgers, The State University of New Jersey
U.S. Department of Veterans Affairs
Subject
Dermatology,General Biochemistry, Genetics and Molecular Biology,Oncology
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献